NCT03999658WithdrawnPhase 2
An Open-label, Multicenter, Global Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Malignancies.
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- Sorrento Therapeutics, Inc.
- Primary Endpoint
- Objective Response Rate
Study Overview
Brief Summary
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
Detailed Description
This is an open-label, multicenter, global Phase 2 basket study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of STI-3031 in patients with selected relapsed or refractory (R/R) malignancies. The study will be conducted as separate Phase 2, single arm substudies for each of the indications below:
- Extranodal NK/T-cell lymphoma (ENKTL)
- Peripheral T-cell lymphomas (PTCL)
- Diffuse large B-cell lymphoma (DLBCL) with PD-L1 gene translocation, copy gain, amplification, polysomy detectable by a fluorescence in situ hybridization (FISH) assay or Epstein-Barr virus positivity (EBV+) as assessed by EBV-encoded small RNA (EBER) testing
- Biliary tract cancers (BTC) (intrahepatic cholangiocarcinoma), extrahepatic cholangiocarcinoma or gallbladder cancer)
All participants will receive the study intervention, STI-3031.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Documented histologically confirmed diagnoses of Extranodal NK/T-cell lymphoma, Peripheral T-cell lymphoma, Diffuse Large B-cell lymphoma (with a PD-L1 gene abnormality or Epstein-Barr virus positivity, or biliary tract cancer.
- •Prior treatment:
- •Extranodal NK/T-cell lymphoma: Must have received at least 1 previous line of systemic therapy including an asparaginase-based regimen.
- •Peripheral T-cell lymphoma: must have received at least 1 previous line of systemic multi-agent chemotherapy. Participants with anaplastic large cell lymphoma (ALCL) must have received brentuximab vedotin
- •Diffuse Large B-cell lymphoma: Must have received at least 2 previous lines of systemic therapy including an anti-CD20 antibody
- •Biliary Tract Cancer: Must have received at least 1 previous line of systemic therapy including gemcitabine with or without platinum
- •Documented disease progression during or after the last therapy
- •If not previously treated with transplant, Investigator considers the participant ineligible for transplant
- •Measurable disease
- •Adult age (as defined by respective country) at time of signing informed consent form (ICF)
- •Must be able to understand the nature of the study and provide a signed and dated, written ICF prior to any study-specific procedures, sample collections and analyses
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
- •Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment and radiopharmaceuticals are permitted if more than 8 weeks have elapsed since the end of treatment
- •At least 14 days or 5 half-lives must have elapsed since the last chemotherapy, immunotherapy, biological or investigational therapy, and have recovered from toxicities associated with such treatment to < Grade 2
- •Adequate hematologic, renal and hepatic function
- •Females of childbearing potential (FCBP) must agree to use a reliable form of contraceptive during the study treatment period and for at least 90 days following the last dose of study intervention
- •Male participants must agree to use barrier contraception (i.e., condoms) for the duration of the study and for at least 90 days after the last dose of study intervention
- •Predicted life expectancy of at least 16 weeks
Exclusion Criteria
- •Current participation in another therapeutic clinical trial
- •Prior treatment with an anti-PD-L1 or anti-PD-1 antibody
- •Patients with symptomatic central nervous system (CNS) metastases unless considered adequately treated and controlled for at least 2 weeks
- •Prior hematopoietic stem cell transplantation
- •History of other previous cancer that would interfere with the determination of safety or efficacy
- •Any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo, hormone replacement therapy for stable thyroid diseases and Type 1 diabetes mellitus
- •Apparent active or latent tuberculosis (TB) infection
- •Seropositive for or have active infection with hepatitis C virus (HCV), unless HCV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy
- •Seropositive for or have active viral infection with hepatitis B virus (HBV), unless HBV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy
- •Seropositive for or active viral infection with HIV, unless the following are met:
- •CD4+ T-cell (CD4+) counts ≥ 350 cells/uL; and
- •Participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to screening and have HIV viral load < 400 copies/mL; and
- •Participant has not had acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 12 months prior to screening
- •Active infection (viral, bacterial, or fungal) requiring intravenous (IV) systemic therapy within 14 days
- •Evidence of bleeding diathesis or coagulopathy.
- •Significant proteinuria
- •Conditions requiring chronic steroid use (> 10 mg/day of prednisone or equivalent).
- •Recent history of attenuated viral vaccination within 30 days prior to the first dose of study intervention
- •Herbal preparations/medications are not allowed throughout the treatment period unless first discussed with and approved by the Medical Monitor
- •History of severe hypersensitivity reactions to other monoclonal antibodies or known hypersensitivity to the study intervention or its excipients.
- •Known current drug or alcohol abuse
- •Major surgical procedures ≤ 28 days prior to the first dose of study intervention, or minor surgical procedures ≤7 days prior to the first dose of study intervention
- •Pregnant or lactating
- •Any of the following cardiac diseases currently or within the last 6 months:
- •QT interval corrected using Fridericia's formula >450 milliseconds in men and > 470 milliseconds in women (up to 480 milliseconds may be allowed after discussion between the Investigator and the Medical Monitor).
- •Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
- •Unstable angina pectoris
- •Congestive heart failure (New York Heart Association ≥ Grade 2)
- •Acute myocardial infarction
- •Clinically significant conduction abnormality not controlled with pacemaker or medication
- •Significant ventricular or supraventricular arrhythmias (Participants with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible.)
- •Underlying medical conditions that, in the opinion of the investigator and/or medical monitor, will render the administration of study drug hazardous or obscure the interpretation of safety or efficacy results
Outcomes
Primary Outcomes
Objective Response Rate
Time Frame: Approximately 24 months
Percentage of participants achieving a Complete Response (CR) or Partial Response (PR) at any time during the study as assessed by an Independent Response Committee (IRC) per the Lugano criteria with LYRIC modification or RECIST 1.1
Secondary Outcomes
- Area Under the Curve (AUC) of the blood levels of STI-3031(Approximately 24 months)
- Duration of Complete Response Rate(Approximately 24 months)
- Event free survival(Approximately 24 months)
- Immunogenicity(Approximately 24 months)
- Duration of Response(Approximately 24 months)
- Maximum Plasma Concentration (Cmax) of STI-3031(Approximately 24 months)
- Complete Response Rate(Approximately 24 months)
- Objective Response Rate by treating physician(Approximately 24 months)
- Progressive-free survival(Approximately 24 months)
- 12-month Progressive-free survival(Approximately 30 months (18 months for enrollment plus 12 months follow-up for the last participant enrolled))
- Time of Maximum concentration observed (Tmax) of STI-3031(Approximately 24 months)
- Half-life (t1/2) of STI-3031(Approximately 24 months)
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of STI-3031(Approximately 24 months)
Investigators
Similar Trials
Unknown
Phase 2
A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast CancerRecurrent Breast CancerMetastatic Breast CancerNCT01351597Korean Breast Cancer Study Group51
Terminated
Phase 2
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)Recurrent Glioblastoma Multiforme (GBM)NCT00290771Novartis231
Recruiting
Phase 1
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)NCT05934513Genfleet Therapeutics (Shanghai) Inc.95
Completed
Phase 2
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical CancerRecurrent Cervical CancerMetastatic Cervical CancerNCT04380805Akeso30
Terminated
Phase 2
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.High Risk MDSNCT02159040Novartis Pharmaceuticals1